胃癌化学抵抗的细胞和分子机制
Zonglin Li1, Xingming Shu1, Xin Liu1
1Department of General Surgery (Gastrointestinal Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
International journal of general medicine
|September 3, 2024
概括
化学抵抗是胃癌 (GC) 治疗的一个主要挑战,导致复发和死亡. 了解GC化学抵抗机制是开发更好的治疗方法和改善患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 胃癌 (GC) 是一种普遍存在的消化道恶性瘤.
- 化疗对GC治疗至关重要,但面临着重大挑战.
- 在GC中,化学抵抗导致长期的不良结果,包括瘤复发,转移和死亡率.
研究的目的:
- 阐明胃癌中化学抵抗的详细细胞和分子机制.
- 确定在GC中克服化学抵抗的特定治疗点.
- 提供关于GC化学抵抗的当前知识的综合总结.
主要方法:
- 文献综述和对胃癌化学抵抗现有研究的综合.
- 对参与GC化学抵抗的细胞和分子通路的分析.
- 确定导致GC治疗失败的关键因素.
主要成果:
- 化疗抵抗显著阻碍了化疗在胃癌患者的有效性.
- 各种细胞和分子机制有助于GC中化学抵抗的发展.
- 了解这些机制对于开发克服抗性的策略至关重要.
结论:
- 阐明GC化学抵抗机制对于提高治疗疗效至关重要.
- 识别新的治疗点可以帮助克服化疗抵抗并改善患者的预后.
- 本综述巩固了当前的理解,以指导未来的研究和临床应用.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154


